Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2757798
Reference Type
Journal Article
Subtype
Review
Title
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
Author(s)
Casa, AJ; Dearth, RK; Litzenburger, BC; Lee, AV; Cui, X
Year
2008
Is Peer Reviewed?
Yes
Journal
Frontiers in Bioscience
ISSN:
1093-9946
EISSN:
1093-4715
Volume
13
Page Numbers
3273-3287
Language
English
PMID
18508432
DOI
10.2741/2925
Abstract
The insulin-like growth factor (IGF) ligands stimulate cellular proliferation and survival by activating the type I insulin-like growth factor receptor (IGF-IR). As a result, the IGF signaling system is implicated in a number of cancers, including those of the breast, prostate, and lung. In addition to mitogenic and anti-apoptotic roles that may directly influence tumor development, IGF-IR also appears to be a critical determinant of response to numerous cancer therapies. This review describes the role of the IGF-IR pathway in mediating resistance to both general cytotoxic therapies, such as radiation and chemotherapy, and targeted therapies, such as tamoxifen and trastuzumab. It concludes with a description of approaches to target IGF-IR and argues that inhibition of IGF signaling, in conjunction with standard therapies, may enhance the response of cancer cells to multiple modalities.
Tags
PFAS
•
Additional PFAS (formerly XAgency)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity